EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK ‐positive anaplastic large‐cell lymphoma

Jietian Jin iD, Wenjian Cen iD, Qin Yan iD, Yangshan Chen iD, Chaoyun Huang iD, Yanfeng Feng iD, Neng Jiang iD

Histopathology · 2026-12 · 89 (6) · 1031-1041

DOI: 10.1111/his.70257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 31.07.2026. Verfasst von Jietian Jin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen Unive…. Hauptthemen laut MEDLINE: Ki-1 Antigen, Lung Neoplasms, Lymphoma, Large-Cell, Anaplastic, Biomarkers, Tumor. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although ALK rearrangement is a well‐established alteration in lung adenocarcinoma (LUAD), CD30 expression in this setting remains poorly characterized. We analysed a series of poorly differentiated LUADs with concurrent ALK and CD30 expression that closely resemble ALK‐positive anaplastic large‐cell lymphoma (ALCL), focusing on their clinicopathological and molecular features as well as potential diagnostic and therapeutic implications. Methods and results We retrospectively searched multi‐institutional case databases and the published literature, ultimately identifying eight cases of poorly differentiated LUAD with concurrent ALK and CD30 expression. Clinical, histomorphological, immunohistochemical and molecular features, along with treatment responses and outcomes, were systematically recorded and analysed. Patients had a median age of 47.5 years (range, 26–67 years), with equal sex distribution and all presented with advanced‐stage disease (stage III–IV). The diagnostic challenge posed by these tumours was substantial: four cases were initially radiologically suspected to represent aggressive lymphoma, and one patient had been misdiagnosed and actively treated as ALCL at an outside institution before referral. Histologically, all tumours consisted of diffuse sheets of markedly pleomorphic large cells with prominent nucleoli and brisk mitotic activity, a morphology strikingly reminiscent of ALCL hallmark cells. Most cases showed diffuse or focal expression of epithelial markers, with variable TTF‐1 positivity. The Ki‐67 proliferation index ranged from 50% to 95%. All cases co‐expressed ALK and CD30, lacked lymphoma‐associated immunophenotypic markers and showed no evidence of clonal T‐cell receptor gene rearrangement (TCR). Molecular sequencing confirmed that all ALK fusion breakpoints corresponded to previously described LUAD‐associated variants, and all patients achieved marked responses to ALK‐directed therapy.

Conclusions

Poorly differentiated LUAD with dual ALK and CD30 expression is a rare but diagnostically challenging entity that can closely simulate ALK‐positive ALCL. Awareness of this mimic is critical to ensure accurate diagnosis and timely initiation of appropriate targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ki-1 AntigenLung NeoplasmsLymphoma, Large-Cell, AnaplasticBiomarkers, TumorAdenocarcinomaAdenocarcinoma of LungHumansAnaplastic Lymphoma KinaseMaleAdultFemaleAgedMiddle AgedDiagnosis, DifferentialRetrospective StudiesReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

ALK‐positive anaplastic large‐cell lymphomaCD30lung adenocarcinoma

Substanzen

Ki-1 AntigenAnaplastic Lymphoma KinaseALK protein, humanBiomarkers, TumorReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
  • Department of Molecular Diagnostics, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
  • Department of Pathology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, People's Republic of China.

ORCID-Profile: Jietian Jin, Wenjian Cen, Qin Yan, Yangshan Chen, Chaoyun Huang, Yanfeng Feng, Neng Jiang

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Jin, J., Cen, W., Yan, Q., Chen, Y., Huang, C., Feng, Y., & Jiang, N. (2026). Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK ‐positive anaplastic large‐cell lymphoma. Histopathology, 89(6), 1031-1041. https://doi.org/10.1111/his.70257

Vancouver

Jin J, Cen W, Yan Q, Chen Y, Huang C, Feng Y, et al. Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK ‐positive anaplastic large‐cell lymphoma. Histopathology. 2026;89(6):1031-1041. doi:10.1111/his.70257

BibTeX
@article{Jin2026,
  author = {Jin, Jietian and Cen, Wenjian and Yan, Qin and Chen, Yangshan and Huang, Chaoyun and Feng, Yanfeng and Jiang, Neng},
  title = {Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK ‐positive anaplastic large‐cell lymphoma},
  journal = {Histopathology},
  year = {2026},
  volume = {89},
  number = {6},
  pages = {1031--1041},
  doi = {10.1111/his.70257}
}
Kostenlos starten →